Hypothyroidism in Patients with Thalassemia Syndromes

Magro, Saverio; Puzzonia, Pasquale; Consarino, Caterina; Galati, M. C.; Morgione, S.; Porcelli, Daniele; Grimaldi, Settimio; Tancre, D.; Arcuri, Vanessa; Santis, Valeria De; Alberti, Alberto

doi:10.1159/000205032

Cited by 51 publications

(33 citation statements)

References 6 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…This is contrary to previous studies [71,72] including a 12-year longitudinal study by Filosa et al [72] 7 years earlier which showed no association between ferritin levels or transfusion statuswith worsening thyroid function. Some studies have reported a high prevalence of primary hypothyroidism reaching up to 17% -18% [7,73] whereas others have reported a low prevalence of 0% -9% [74,75]. Shamshirsaz et al [1] demonstrated a prevalence of 7.7% in their study similar to the Italian study group [35] who found 6.2% patients to be hypothyroid where as Aydinok et al [47] showed the prevalence to be higher at 16%.…”

Section: Open Access Ojemdmentioning

confidence: 73%

A Review of Endocrine Disorders in Thalassaemia

De¹,

Mistry²,

Wright³

et al. 2014

OJEMD

View full text Add to dashboard Cite

Endocrine dysfunction in thalassaemia is amongst the most common complication and is principally attributed to excessive iron overload and suboptimal chelation. The prevalence is quite high particularly in multiethnic populations but determining the prevalence is often difficult due to the widespread heterogeneity of the population and timing of exposure to chelation therapy. Disturbances in growth, pubertal development, abnormal gonadal functions, impaired thyroid, parathyroid and adrenal functions, diabetes and disorderly bone growth are commonly encountered. Early detection and institution of appropriate transfusion regimen and chelation therapy and treatment of complications are the keys to managing this population including regular follow. In this article, we review the literature in relation to the various endocrine complications encountered in thalassaemia.

show abstract

Section: Open Access Ojemdmentioning

confidence: 73%

A Review of Endocrine Disorders in Thalassaemia

De¹,

Mistry²,

Wright³

et al. 2014

OJEMD

View full text Add to dashboard Cite

show abstract

“…Thyroid dysfunction has been reported in 13–60% of patients with thalassemia, but its severity is variable in different series. Some studies reported a high prevalence of primary hypothyroidism, reaching up to 17–18% [18,19], While others reported low prevalence of 0–9% [20,21]. It is important to note that even in the studies in which the prevalence of overt hypothyroidism as a complication of thalassemia major is relatively low, milder forms of thyroid dysfunction are much more common [18,20,22], though again there are wide variations in different reports.…”

Section: Discussionmentioning

confidence: 99%

“…Some studies reported a high prevalence of primary hypothyroidism, reaching up to 17–18% [18,19], While others reported low prevalence of 0–9% [20,21]. It is important to note that even in the studies in which the prevalence of overt hypothyroidism as a complication of thalassemia major is relatively low, milder forms of thyroid dysfunction are much more common [18,20,22], though again there are wide variations in different reports. These discrepancies can not be attributed to differences in patients' ages, but rather to difference treatment protocols, including differing transfusion rates and chelation therapies [21].…”

Section: Discussionmentioning

confidence: 99%

Metabolic and endocrinologic complications in beta-thalassemia major: a multicenter study in Tehran

et al. 2003

View full text Add to dashboard Cite

BackgroundThe combination of transfusion and chelation therapy has dramatically extended the life expectancy of thalassemic patients. The main objective of this study is to determine the prevalence of prominent thalassemia complications.MethodsTwo hundred twenty patients entered the study. Physicians collected demographic and anthropometric data and the history of therapies as well as menstrual histories. Patients have been examined to determine their pubertal status. Serum levels of 25(OH) D, calcium, phosphate, iPTH were measured. Thyroid function was assessed by T3, T4 and TSH. Zinc and copper in serum were determined by flame atomic absorption spectrophotometry. Bone mineral density (BMD) measurements at lumbar and femoral regions have been done using dual x-ray absorptiometry. The dietary calcium, zinc and copper intakes were estimated by food-frequency questionnaires.ResultsShort stature was seen in 39.3% of our patients. Hypogonadism was seen in 22.9% of boys and 12.2% of girls. Hypoparathyroidism and primary hypothyroidism was present in 7.6% and 7.7% of the patients. About 13 % of patients had more than one endocrine complication with mean serum ferritin of 1678 ± 955 micrograms/lit. Prevalence of lumbar osteoporosis and osteopenia were 50.7% and 39.4%. Femoral osteoporosis and osteopenia were present in 10.8% and 36.9% of the patients. Lumbar BMD abnormalities were associated with duration of chelation therapy. Low serum zinc and copper was observed in 79.6% and 68% of the study population respectively. Serum zinc showed significant association with lumbar but not femoral BMD. In 37.2% of patients serum levels of 25(OH) D below 23 nmol/l were detected.ConclusionHigh prevalence of complications among our thalassemics signifies the importance of more detailed studies along with therapeutic interventions.

show abstract

“…Chronic hypoxia due to anaemia, viral infections and individual susceptibility are other factors which could potentiate the toxicity of iron deposition and contribute to endocrine dysfunction. 2,3 Detecting the exact prevalence of endocrinopathies in patients with thalassaemia is challenging due to variability in the study population. This partly relates to ages of patients being studied and the adequacy of chelation therapy.…”

Section: Introductionmentioning

confidence: 99%

Evaluation and management of diabetes in patients with thalassaemia major

Karuppiah

2016

J of Cey Coll of Phy

View full text Add to dashboard Cite

Hypothyroidism in Patients with Thalassemia Syndromes

Cited by 51 publications

References 6 publications

A Review of Endocrine Disorders in Thalassaemia

A Review of Endocrine Disorders in Thalassaemia

Metabolic and endocrinologic complications in beta-thalassemia major: a multicenter study in Tehran

Evaluation and management of diabetes in patients with thalassaemia major

Contact Info

Product

Resources

About